Mirati Therapeutics, Inc. (MRTX) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Total revenue	13.7	7.2	0.9	5.4	5.4	0.7	0.3	71.8
Total revenue growth	155.3%	910.9%	212.4%	-92.4%			-82.5%	528.4%
Revenue
Total revenue	13.7	7.2	0.9	5.4	5.4	0.7	0.3	71.8
Total revenue growth	155.3%	910.9%	212.4%	-92.4%			-82.5%	528.4%
Operating expenses
Cost of product revenue	1.0	0.6	0.6
Cost of product revenue - intangible asset amortization	0.3	0.3
Research and development	124.2	126.7	141.2	131.1	128.3	131.0	153.8	116.1
Selling, general and administrative	75.5	73.5			54.2	54.0
Total operating expenses	201.0	201.0	212.7	191.9	182.6	184.9	197.4	151.3
Loss from operations	-187.3	-193.8	-211.7	-186.4	-177.2	-184.2	-197.1	-79.5
Operating margin	-1367.9%	-2704.4%	-22668.4%	-3432.9%	-3304.8%	-25982.8%	-65911.4%	-110.7%
Other income (expense), net	10.4	9.2	9.5	13.1	0.8	-4.2	-2.5	2.7
Net loss	-176.9	-184.6	-202.5	-173.6	-176.4	-188.4	-199.6	-80.1
Foreign currency translation adjustment	0.0	0.0	-0.1	-9.5
Unrealized gain (loss) on available-for-sale investments	0.0	2.0			-0.9	-4.8
Comprehensive loss	-176.9	-182.6	-200.1	-183.0	-177.4	-193.2	-200.1	-80.1

Basic net loss per share (USD per share)	($3.04)	($3.18)	($3.52)	($3.09)	($3.18)	($3.40)	($3.76)	($1.55)
Diluted net loss per share (USD per share)	($3.04)	($3.18)	($3.52)	($3.09)	($3.18)	($3.40)	($3.76)	($1.55)

Weighted average common shares outstanding, basic (shares)	58.2	58.0	56.2	56.2	55.6	55.5	51.9	51.7
Weighted average common shares outstanding, diluted (shares)	58.2	58.0	56.2	56.2	55.6	55.5	51.9	51.7